The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
Abstract
Objective: This phase 1 trial set out to examine the safety of a bacteriophage-based preparation for difficult-to-treat wounds. Method: The intention-to-treat sample comprised 42 patients with chronic venous leg ulcers (VLUs); 39 patients completed the trial. The ulcers were treated for 12 weeks with either a saline control or bacteriophages targeted against Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. Follow-up continued until week 24. Results: No adverse events were attributed to the study product. No signifi cant difference (p>0.05) was determined between the test and control groups for frequency of adverse events, rate of healing, or frequency of healing. Conclusion: This study found no safety concerns with the bacteriophage treatment. Efficacy of the preparation will need to be evaluated in a phase II efficacy study. Declaration of interest: One of the authors (AS) holds an equity interest in Intralytix. The other authors do not have any interest in commercial activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence
Singer, J. D., & Willett, J. B. (2003) · doi:10.1093/acprof:oso/9780195152968.001.0001 · Cited by 10,647
Antibiotic resistance of bacteria in biofilms
Stewart, P. S., & William Costerton, J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05321-1 · Cited by 4,585
James, G. A., Swogger, E., Wolcott, R., Pulcini, E. D., Secor, P., Sestrich, J., Costerton, J. W., & Stewart, P. S. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2007.00321.x · Cited by 1,543
Self-citationDowd, S. E., Sun, Y., Secor, P. R., Rhoads, D. D., Wolcott, B. M., James, G. A., & Wolcott, R. D. (2008) · BMC Microbiology · doi:10.1186/1471-2180-8-43 · Cited by 784
Self-citationLactoferrin: Lactoferrin: an important host defence against microbial and viral attack
Valenti, P., & Antonini, G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5372-0 · Cited by 488
Dowd, S. E., Wolcott, R. D., Sun, Y., McKeehan, T., Smith, E., & Rhoads, D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003326 · Cited by 481
Self-citationBacteriophages show promise as antimicrobial agents
Alisky, J., Iczkowski, K., Rapoport, A., & Troitsky, N. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)92874-2 · Cited by 318
Quantitative assessment of the germicidal efficacy of ultrasonic energy
Scherba, G., Weigel, R. M., & O'Brien, W. D. (1991) · Applied and Environmental Microbiology · doi:10.1128/aem.57.7.2079-2084.1991 · Cited by 305
A study of biofilm-based wound management in subjects with critical limb ischaemia
Wolcott, R. D., & Rhoads, D. D. (2008) · Journal of Wound Care · doi:10.12968/jowc.2008.17.4.28835 · Cited by 243
Self-citationMarkoishvili, K., Tsitlanadze, G., Katsarava, R., Glenn, J., Morris Jr., M. D., & Sulakvelidze, A. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01451.x · Cited by 243
Self-citation
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 998
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa
Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., & Turner, P. E. (2016) · Scientific Reports · doi:10.1038/srep26717 · Cited by 715
Wittebole, X., De Roock, S., & Opal, S. M. (2014) · Virulence · doi:10.4161/viru.25991 · Cited by 599
Importance of prophages to evolution and virulence of bacterial pathogens
Fortier, L.-C., & Sekulovic, O. (2013) · Virulence · doi:10.4161/viru.24498 · Cited by 577
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., & Narayan, D. (2018) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoy005 · Cited by 501
Roach, D. R., Leung, C. Y., Henry, M., Morello, E., Singh, D., Di Santo, J. P., Weitz, J. S., & Debarbieux, L. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.06.018 · Cited by 484
Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections
Principi, N., Silvestri, E., & Esposito, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00513 · Cited by 454
Genetically Engineered Phages: a Review of Advances over the Last Decade
Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J., & Lu, T. K. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00069-15 · Cited by 427
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review
Uyttebroek, S., Chen, B., Onsea, J., Ruythooren, F., Debaveye, Y., Devolder, D., Spriet, I., Depypere, M., Wagemans, J., Lavigne, R., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00612-5 · Cited by 411
Clinical Aspects of Phage Therapy
Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., Fortuna, W., Letkiewicz, S., Szufnarowski, K., Pawełczyk, Z., Rogóż, P., Kłak, M., Wojtasik, E., et al. (2012) · Advances in Virus Research · doi:10.1016/b978-0-12-394438-2.00003-7 · Cited by 373
Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles
Furfaro, L. L., Payne, M. S., & Chang, B. J. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00376 · Cited by 362
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Oechslin, F., Piccardi, P., Mancini, S., Gabard, J., Moreillon, P., Entenza, J. M., Resch, G., & Que, Y.-A. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiw632 · Cited by 325
Biotechnological applications of bacteriophages: State of the art
Harada, L. K., Silva, E. C., Campos, W. F., Del Fiol, F. S., Vila, M., Dąbrowska, K., Krylov, V. N., & Balcão, V. M. (2018) · Microbiological Research · doi:10.1016/j.micres.2018.04.007 · Cited by 318
The next generation of bacteriophage therapy
Lu, T. K., & Koeris, M. S. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.028 · Cited by 312
Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options
Chatterjee, M., Anju, C. P., Biswas, L., Anil Kumar, V., Gopi Mohan, C., & Biswas, R. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.11.004 · Cited by 312
Early clinical experience of bacteriophage therapy in 3 lung transplant recipients
Aslam, S., Courtwright, A. M., Koval, C., Lehman, S. M., Morales, S., Furr, C.-L. L., Rosas, F., Brownstein, M. J., Fackler, J. R., Sisson, B. M., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15503 · Cited by 285
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Ding, X., Tang, Q., Xu, Z., Xu, Y., Zhang, H., Zheng, D., Wang, S., Tan, Q., Maitz, J., Maitz, P. K., et al. (2022) · Burns & Trauma · doi:10.1093/burnst/tkac014 · Cited by 277
The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies
Liu, D., Van Belleghem, J. D., de Vries, C. R., Burgener, E., Chen, Q., Manasherob, R., Aronson, J. R., Amanatullah, D. F., Tamma, P. D., & Suh, G. A. (2021) · Viruses · doi:10.3390/v13071268 · Cited by 268
Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
Luong, T., Salabarria, A.-C., & Roach, D. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.014 · Cited by 266
McCallin, S., Alam Sarker, S., Barretto, C., Sultana, S., Berger, B., Huq, S., Krause, L., Bibiloni, R., Schmitt, B., Reuteler, G., et al. (2013) · Virology · doi:10.1016/j.virol.2013.05.022 · Cited by 265
Alternatives to overcoming bacterial resistances: State-of-the-art
Rios, A. C., Moutinho, C. G., Pinto, F. C., Del Fiol, F. S., Jozala, A., Chaud, M. V., Vila, M. M. D. C., Teixeira, J. A., & Balcão, V. M. (2016) · Microbiological Research · doi:10.1016/j.micres.2016.04.008 · Cited by 263
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Belizário, J. E., & Faintuch, J. (2018) · Experientia Supplementum · doi:10.1007/978-3-319-74932-7_13 · Cited by 255
Phages and their potential to modulate the microbiome and immunity
Federici, S., Nobs, S. P., & Elinav, E. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00532-4 · Cited by 222
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Regulation of phage therapy medicinal products: developments, challenges, and opportunities
Fuerst-Wilmes, M., Respondek, V., Schramm, M., Lilienthal, N., Buss, K., & Duechting, A. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1631359 · Cited by 31
Isolation and characterization of novel Fusobacterium nucleatum bacteriophages
Wang, Y., Liu, Z., Chen, Q., Yi, L., Xu, Z., Cai, M., Qin, J., Zhang, Y., Du, G., Hong, J., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.945315 · Cited by 23
Metadata
- Authors
- Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., & Sulakvelidze, A.
- Venue
- Journal of Wound Care
- Publisher
- Mark Allen Group
- Published
- 2009-06
- Volume
- 18
- Issue
- 6
- Pages
- 237-243
- ISSN
- 0969-0700 (ISSN-L)
- 2052-2916
- OpenAlex
- W2097999790
- Cited by
- 468
- References
- 15
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.